Biocon Limited
Biocon is engaged in the business of manufacture of biotechnology products and research services.(Source : 202003-01 Annual Report Page No:195)
What Biocon files
- Updates91
- Others75
- Important67
- Investor Meet62
- Board Meeting23
- PPTs9
Biocon Limited has informed the Exchange about Communication regarding remittance of final dividend for the FY 2025-26
Biocon Limited has scheduled an in-person investor roadshow in Mumbai to interact with analysts and institutional investors through one-on-one and group meetings. No unpublished price sensitive information will be discussed during these interactions.
Biocon Limited has informed the Exchange regarding a press release dated September 08, 2026, titled "Biocon Secures 10-Year Supply Contract for Pertuzumab in Brazil".
Biocon Limited's management will hold a virtual group meeting with analysts and institutional investors on September 4, 2026, during the Nomura Asian Credit Corporate Day 2026.
Biocon has paid its final dividend for the recent financial year. Shareholders received ₹0.50 per equity share directly in their accounts, following approval at the AGM.